Laprituximab emtansine

Laprituximab emtansine (IMGN-289) is an immunotoxin targeting HER1. Laprituximab emtansine is an EGFR antibody-drug conjugate (ADC) consisting of the J2898A antibody, DM1 (anti-microtubule agent) and the SMCC thioether linker. Laprituximab emtansine can be used for cancer research[1][2][3].

1622327-37-0

IMGN-289; J2898A-SMCC-DM1

12352203

Antibody-Drug Conjugates (ADCs) ; EGFR

Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Cancer-Kinase/protease

Cancer

97.66

10 mM in DMSO

[Laprituximabemtansine]

[1]Moradi-Kalbolandi S, et al. Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER. J Pharm Pharmacol. 2018 Jul;70 (7) :841-854. |[2]Yulius Y. et al. Abstract 4513: IMGN289, an EGFR-targeting antibody-drug conjugate, is effective against tumor cells that are resistant to EGFR tyrosine kinase inhibitors. Cancer Res 1 October 2014; 74 (19_Supplement) : 4513. |[3]Hyunseok Kang, et al. Antitumor effect of IMGN289, an anti-EGFR antibody-drug conjugate (ADC), in preclinical models of head and neck squamous cell carcinomas (HNSCC) . Journal of Clinical Oncology. 2014. 32, no. 15_suppl. |[4]Jose F. Ponte, et al. Abstract 5483: Preclinical evaluation of IMGN289, an anti-EGFR antibody-maytansinoid conjugate for the treatment of squamous cell carcinoma of the head and neck. Cancer Res (2013) 73 (8_Supplement) : 5483.

Dry Ice

-80°C, protect from light

http://file.medchemexpress.com/batch_PDF/HY-P99685/Laprituximab-emtansine-SDS-MedChemExpress.pdf

ADC Related

Phase 1

EGFR/ErbB1/HER1